217 related articles for article (PubMed ID: 35580546)
1. Comparative hemostatic efficacy of 4F-PCC in patients with intracranial hemorrhage on factor Xa inhibitors versus warfarin.
Heath M; Hall B; De Leon J; Gillespie R; Hasara S; Henricks B; Lakshmi M; Watson D; Wilson K
Am J Emerg Med; 2022 Jul; 57():149-152. PubMed ID: 35580546
[TBL] [Abstract][Full Text] [Related]
2. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages.
Pham H; Medford WG; Horst S; Levesque M; Ragoonanan D; Price C; Colbassani H; Piper K; Chastain K
Am J Emerg Med; 2022 May; 55():38-44. PubMed ID: 35272069
[TBL] [Abstract][Full Text] [Related]
3. Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage.
Ammar AA; Ammar MA; Owusu KA; Brown SC; Kaddouh F; Elsamadicy AA; Acosta JN; Falcone GJ
Neurocrit Care; 2021 Aug; 35(1):255-261. PubMed ID: 33403588
[TBL] [Abstract][Full Text] [Related]
4. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage.
Vestal ML; Hodulik K; Mando-Vandrick J; James ML; Ortel TL; Fuller M; Notini M; Friedland M; Welsby IJ
J Thromb Thrombolysis; 2022 Jan; 53(1):167-175. PubMed ID: 34101050
[TBL] [Abstract][Full Text] [Related]
5. Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage.
Lipski M; Pasciolla S; Wojcik K; Jankowitz B; Igneri LA
J Thromb Thrombolysis; 2023 Apr; 55(3):519-526. PubMed ID: 36566473
[TBL] [Abstract][Full Text] [Related]
6. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
Costa OS; Connolly SJ; Sharma M; Beyer-Westendorf J; Christoph MJ; Lovelace B; Coleman CI
Crit Care; 2022 Jun; 26(1):180. PubMed ID: 35710578
[TBL] [Abstract][Full Text] [Related]
7. Hemostatic efficacy of four factor prothrombin complex concentrate in intracerebral hemorrhage patients receiving warfarin vs. factor Xa inhibitors.
Pon G; Pelsue B; Reddy ST; Parsha K; Zhang X; Gulbis B; Barreto A; Savitz SI; Escobar M; Allison TA
Thromb Res; 2023 Sep; 229():46-52. PubMed ID: 37406569
[TBL] [Abstract][Full Text] [Related]
8. The use of andexanet alfa and 4-factor prothrombin complex concentrate in intracranial hemorrhage.
Oh ES; Schulze P; Diaz F; Shah K; Rios J; Silverman ME
Am J Emerg Med; 2023 Feb; 64():74-77. PubMed ID: 36463661
[TBL] [Abstract][Full Text] [Related]
9. Impact of timing and dosing of four-factor prothrombin complex concentrate administration on outcomes in warfarin-associated intracranial hemorrhage.
Cicci CD; Weiss A; Dang C; Stanton M; Feldman R
Pharmacotherapy; 2022 May; 42(5):366-374. PubMed ID: 35384000
[TBL] [Abstract][Full Text] [Related]
10. Comparison of 4-factor PCC reversal of apixaban and rivaroxaban versus warfarin for intracranial hemorrhage.
Pasciolla S; Wojcik K; Kavi T; Green D; Shaikh H; Jankowitz B; Igneri LA
J Thromb Thrombolysis; 2022 Jul; 54(1):74-81. PubMed ID: 34837144
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages.
Barra ME; Das AS; Hayes BD; Rosenthal ES; Rosovsky RP; Fuh L; Patel AB; Goldstein JN; Roberts RJ
J Thromb Haemost; 2020 Jul; 18(7):1637-1647. PubMed ID: 32291874
[TBL] [Abstract][Full Text] [Related]
12. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study.
Smith MN; Deloney L; Carter C; Weant KA; Eriksson EA
J Thromb Thrombolysis; 2019 Aug; 48(2):250-255. PubMed ID: 30941571
[TBL] [Abstract][Full Text] [Related]
13. Impact of Factor Xa Inhibitor Reversal with Prothrombin Complex Concentrate in Patients with Traumatic Brain Injuries.
Cooksey GE; Hamilton LA; McMillen JC; Griffard JH; Rowe AS
Neurocrit Care; 2022 Oct; 37(2):471-478. PubMed ID: 35624388
[TBL] [Abstract][Full Text] [Related]
14. Andexanet alfa effectiveness and safety versus four-factor prothrombin complex concentrate (4F-PCC) in intracranial hemorrhage while on apixaban or rivaroxaban: A single-center, retrospective, matched cohort analysis.
Parsels KA; Seabury RW; Zyck S; Miller CD; Krishnamurthy S; Darko W; Probst LA; Latorre JG; Cwikla GM; Feldman EA
Am J Emerg Med; 2022 May; 55():16-19. PubMed ID: 35245776
[TBL] [Abstract][Full Text] [Related]
15. Treatment of adults with intracranial hemorrhage on apixaban or rivaroxaban with prothrombin complex concentrate products.
Castillo R; Chan A; Atallah S; Derry K; Baje M; Zimmermann LL; Martin R; Groysman L; Stern-Nezer S; Minokadeh A; Nova A; Huang W; Cang W; Schomer K
J Thromb Thrombolysis; 2021 Jan; 51(1):151-158. PubMed ID: 32500220
[TBL] [Abstract][Full Text] [Related]
16. Outcomes Associated With 4-Factor Prothrombin Complex Concentrate Administration to Reverse Oral Factor Xa Inhibitors in Bleeding Patients.
Highsmith EA; Morton C; Varnado S; Donahue KR; Sulhan S; Lista A
J Clin Pharmacol; 2021 May; 61(5):598-605. PubMed ID: 33094836
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Hemostatic Outcomes in Patients Receiving Fixed-Dose vs. Weight-Based 4-Factor Prothrombin Complex Concentrate.
Kim C; Cottingham L; Eberwein K; Komyathy K; Ratliff PD
J Emerg Med; 2020 Jul; 59(1):25-32. PubMed ID: 32536491
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of fixed-dose versus variable-dose prothrombin complex concentrate for warfarin reversal.
Bajdas H; Handzel M; Uttaro E; Jones CMC; Kokanovich K; Acquisto NM
Thromb Res; 2022 Jun; 214():76-81. PubMed ID: 35512560
[TBL] [Abstract][Full Text] [Related]
19. High versus low fixed-dose four factor-prothrombin complex concentrate for warfarin reversal in patients with intracranial hemorrhage.
Compton F; Hall J; De Simone N; Usmani A; Sarode R; Burner J
Transfus Apher Sci; 2022 Oct; 61(5):103444. PubMed ID: 35414467
[TBL] [Abstract][Full Text] [Related]
20. Four-factor prothrombin complex concentrate versus andexanet alfa for direct oral anticoagulant reversal.
Koo SJ; Hussain Y; Booth DY; Desai P; Oh ES; Rios J; Audley K
J Am Pharm Assoc (2003); 2024; 64(2):395-401. PubMed ID: 37952844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]